Ozempic and similar drugs may lower cancer risks, study finds

Published



Breakthrough diabetes and weight loss medication may lower a patient’s risks of common cancers closely linked with obesity, a study published on Friday suggests.

Patients taking Ozempic for Type 2 diabetes management developed fewer obesity-related cancers than patients on insulin alone, according to the new study from a team of researchers at Case Western Reserve University School of Medicine.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.